Ireland’s Fight for Friedreich’s Treatment | Dublin News

Ireland’s rare disease community is rallying against the Health Service Executive’s decision to withhold coverage for Skyclarys, the only drug proven to slow Friedreich’s ataxia—a devastating condition affecting around 200 people in the country. With a staggering €280,000 annual cost per patient, campaigners argue their lives are worth more than the price tag and are staging a protest this Sunday after waiting over 740 days for a decision. They’re fighting not just for today, but for future generations, demanding access to treatment that could restore dignity, mobility, and hope. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/caed4cb9912065d0